315 related articles for article (PubMed ID: 18941254)
1. Activation of antigen-specific cytotoxic T lymphocytes by beta 2-microglobulin or TAP1 gene disruption and the introduction of recipient-matched MHC class I gene in allogeneic embryonic stem cell-derived dendritic cells.
Matsunaga Y; Fukuma D; Hirata S; Fukushima S; Haruta M; Ikeda T; Negishi I; Nishimura Y; Senju S
J Immunol; 2008 Nov; 181(9):6635-43. PubMed ID: 18941254
[TBL] [Abstract][Full Text] [Related]
2. The epitope detected by cytotoxic T lymphocytes against thymus leukemia (TL) antigen is TAP independent.
Tsujimura K; Obata Y; Iwase S; Matsudaira Y; Ozeki S; Takahashi T
Int Immunol; 2000 Sep; 12(9):1217-25. PubMed ID: 10967016
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells pulsed with exogenous hepatitis B surface antigen particles efficiently present epitopes to MHC class I-restricted cytotoxic T cells.
Stober D; Trobonjaca Z; Reimann J; Schirmbeck R
Eur J Immunol; 2002 Apr; 32(4):1099-108. PubMed ID: 11920577
[TBL] [Abstract][Full Text] [Related]
4. MHC class I expression and CD8+ T cell development in TAP1/beta 2-microglobulin double mutant mice.
Ljunggren HG; Van Kaer L; Sabatine MS; Auchincloss H; Tonegawa S; Ploegh HL
Int Immunol; 1995 Jun; 7(6):975-84. PubMed ID: 7577806
[TBL] [Abstract][Full Text] [Related]
5. Differential reactivity of residual CD8+ T lymphocytes in TAP1 and beta 2-microglobulin mutant mice.
Ljunggren HG; Van Kaer L; Ashton-Rickardt PG; Tonegawa S; Ploegh HL
Eur J Immunol; 1995 Jan; 25(1):174-8. PubMed ID: 7843229
[TBL] [Abstract][Full Text] [Related]
6. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine.
Leitch J; Fraser K; Lane C; Putzu K; Adema GJ; Zhang QJ; Jefferies WA; Bramson JL; Wan Y
J Immunol; 2004 May; 172(9):5200-5. PubMed ID: 15100257
[TBL] [Abstract][Full Text] [Related]
7. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.
Stober D; Jomantaite I; Schirmbeck R; Reimann J
J Immunol; 2003 Mar; 170(5):2540-8. PubMed ID: 12594280
[TBL] [Abstract][Full Text] [Related]
8. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
9. Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes.
Dadaglio G; Morel S; Bauche C; Moukrim Z; Lemonnier FA; Van Den Eynde BJ; Ladant D; Leclerc C
Int Immunol; 2003 Dec; 15(12):1423-30. PubMed ID: 14645151
[TBL] [Abstract][Full Text] [Related]
10. Identification of sequences in the human peptide transporter subunit TAP1 required for transporter associated with antigen processing (TAP) function.
Ritz U; Momburg F; Pircher HP; Strand D; Huber C; Seliger B
Int Immunol; 2001 Jan; 13(1):31-41. PubMed ID: 11133832
[TBL] [Abstract][Full Text] [Related]
11. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens.
Haicheur N; Bismuth E; Bosset S; Adotevi O; Warnier G; Lacabanne V; Regnault A; Desaymard C; Amigorena S; Ricciardi-Castagnoli P; Goud B; Fridman WH; Johannes L; Tartour E
J Immunol; 2000 Sep; 165(6):3301-8. PubMed ID: 10975847
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
[TBL] [Abstract][Full Text] [Related]
13. Impaired transporter associated with antigen processing (TAP) function attributable to a single amino acid alteration in the peptide TAP subunit TAP1.
Ritz U; Drexler I; Sutter D; Abele R; Huber C; Seliger B
J Immunol; 2003 Jan; 170(2):941-6. PubMed ID: 12517960
[TBL] [Abstract][Full Text] [Related]
14. Human MHC class I transgenic mice deficient for H2 class I expression facilitate identification and characterization of new HLA class I-restricted viral T cell epitopes.
Cheuk E; D'Souza C; Hu N; Liu Y; Lang H; Chamberlain JW
J Immunol; 2002 Nov; 169(10):5571-80. PubMed ID: 12421934
[TBL] [Abstract][Full Text] [Related]
15. Different MHC class I heavy chains compete with each other for folding independently of beta 2-microglobulin and peptide.
Tourdot S; Nejmeddine M; Powis SJ; Gould KG
J Immunol; 2005 Jan; 174(2):925-33. PubMed ID: 15634915
[TBL] [Abstract][Full Text] [Related]
16. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
Machy P; Serre K; Baillet M; Leserman L
J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
[TBL] [Abstract][Full Text] [Related]
17. The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes.
Schirmbeck R; Stober D; El-Kholy S; Riedl P; Reimann J
J Immunol; 2002 Jun; 168(12):6253-62. PubMed ID: 12055239
[TBL] [Abstract][Full Text] [Related]
18. Priming of immune responses against transporter associated with antigen processing (TAP)-deficient tumours: tumour direct priming.
Li XL; Zhang D; Knight D; Odaka Y; Glass J; Mathis JM; Zhang QJ
Immunology; 2009 Nov; 128(3):420-8. PubMed ID: 20067541
[TBL] [Abstract][Full Text] [Related]
19. Cancer prevention with semi-allogeneic ES cell-derived dendritic cells.
Fukuma D; Matsuyoshi H; Hirata S; Kurisaki A; Motomura Y; Yoshitake Y; Shinohara M; Nishimura Y; Senju S
Biochem Biophys Res Commun; 2005 Sep; 335(1):5-13. PubMed ID: 16026756
[TBL] [Abstract][Full Text] [Related]
20. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S
J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
